Questions discussed in this category


Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?


Papers discussed in this category


Medical and pediatric oncology, 1981

Fertil. Steril., 2013 Sep 05

N. Engl. J. Med.,

Nature medicine, 2015-02

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Blood, 2013-05-02

Cochrane Database Syst Rev, 2012 Jun 13

N Engl J Med,

Blood, 2006 Sep 28

J Clin Oncol, 2010 Apr 20

J Clin Oncol,

Clin Infect Dis,

American journal of hematology, 2020 Dec 08

Blood cancer journal, 2023 Oct 11

Bone marrow transplantation, 2020 Dec 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16

Archives of drug information, 2008-12

Bone marrow transplantation, 2003 Jul

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22

Leukemia, 2005 Apr

Transplantation and cellular therapy, 2021 Oct 02